Grzegorz Madej
Wroclaw, DS, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study.
Journal: Clinical and experimental hepatology
Published: January 21, 2019
Immunodeficiency caused by cirrhosis.
Journal: Clinical and experimental hepatology
Published: November 21, 2017
Impact of selected predictive factors on sustained virologic response in HCV genotype 4 infected patients treated with pegylated interferon alpha and ribavirin
Journal: Przeglad epidemiologiczny
Published: September 06, 2017
Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4.
Journal: Przeglad gastroenterologiczny
Published: December 01, 2016
Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study.
Journal: Clinical and experimental hepatology
Published: October 29, 2016
Prevalence of HCV genotypes in Poland - the EpiTer study.
Journal: Clinical and experimental hepatology
Published: September 12, 2016
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Journal: Alimentary pharmacology & therapeutics
Published: July 04, 2016
The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin.
Journal: Clinical and experimental hepatology
Published: June 20, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026